Background Dupuytren’s disease leads to progressive finger contractures, limiting hand function. Traditional treatment consists of open partial fasciectomy, which requires hospitalisation, anaesthesia and physiotherapy. Recent introduction of Clostridium hystoliticum collagenase into treatment has minimised the economic impact. Purpose To evaluate the efficacy, safety and financial impact of collagenase versus fasciectomy after its introduction in the hospital. Materials and methods A retrospective observational study was performed in a 400-bed university hospital. All patients treated with collagenase since May 2012 were enrolled in the study. Data were collected from medical histories to study efficacy and safety: sex, age, concomitant disease, pharmacotherapeutic history, previous operations and adverse events. We considered treatment was effective when residual contracture was <5º after 4 weeks of collagenase injection. Costs of surgery and consultation were obtained from the GECLIF (Financial Clinical Management) application. The cost of collagenase was calculated based on the average price of its acquisition by the pharmacy. The average cost of fasciectomy includes costs of surgery, hospital stay and associated consultations. Average cost of treatment with collagenase includes the cost of the drug and associated consultations. We compared average costs between the two treatments using the T-Student-Fisher Test. Confidence intervals were calculated for a confidence level of 95% (CI95%) and p values ≤0.05 were considered statistically significant. Results Nine subjects (7 men and 2 women) with an average age of 68 years (range 62–76), diagnosed with Dupuytren’s contracture with palpable cord were enrolled in the study. 55.6% had relapsed after previous surgery. Injectable collagenase was administrated according to Product Information sheet into the metacarpophalangeal joints (66.7% of patients) or interphalangeal joints (33.3% of patients). Residual contracture <5º was achieved in 88.9% (n = 8) of patients. None experienced relapse. One was recently treated, so we have no efficacy results. Mild to moderate adverse events were reported in 88.9% of patients that resolved with appropriate treatment. These included peripheral oedema and hematoma (77.8%), skin lacerations at injection site (44.4%), paresthesia and pain (11.1%), scab, erythema or pruritus (33.3%). Average cost per patient for fasciectomy was 1,503 € and for treatment with collagenase was 923 €. Collagenase treatment cost an average 580 € (509.51–651.06 €, CI95%; p < 0.001) less per patient than fasciectomy. Conclusions Treatment for Dupuytren’s contracture with collagenase is effective and well tolerated in most of patients. It represents a decrease of 38.6% in costs to hospital versus the average cost of fasciectomy per patient. No conflict of interest.
e20631 Background: To date, there are no robust studies in real world practice describing the use of IO (immuno-oncology) treatments in advanced/metastatic (adv/m) NSCLC. The available evidence in Europe is limited to observational studies of small size. This study aims to understand the impact of IO in adv/mNSCLC and study the profile of patients currently receiving these treatments. Methods: 20,157 cases of 1st and 2nd line adv/mNSCLC patients between October 2016 and September 2018 in EU5 (France, Germany, Spain, Italy, UK) were identified within Oncology Dynamics, an IQVIA oncology syndicated cross sectional survey collecting anonymized patient-level data. Patient profile was described, and two groups were created to assess differences in the use of IO treatments (nivolumab, pembrolizumab, atezolizumab, ipilimumab, durvalumab) across 2 time periods: #1 October 2016 - September 2017 (n = 9,310); #2 October 2017 - September 2018 (n = 10,847). Results: IO treatments increased 15% in 1st line adv/mNSCLC (13% in non-squamous and 23% in squamous histology) and 11% in 2nd line across periods; reaching treatment shares of 20.3% and 67.9% in 1st line and 2nd line in Period 2. Within IO-treated patients, 9.5% in 1st line and 13.6% in 2nd line had ECOG ≥2, and 27% were > 71 years old. The use of IO in 1st line patients without mutations (EGFR/ALK/ROS1/BRAF) increased by 24%, while standard chemotherapy decreased by 21%. Conclusions: IO treatments had a rapid adoption in Europe last year, influenced by its approval in 1st line adv/mNSCLC and by clinical guidelines recommendations. Ongoing clinical trials may suggest a growing trend in the future that could potentially impact in healthcare systems. In addition, real world patients treated with IO are older and have a worse performance status than those widely included in clinical trials. An evaluation of these results sheds light into IO treatments in NSCLC and may contribute to the design of real-world studies to generate new evidence and optimize the use of these class of drugs in clinical practice.[Table: see text]
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.